ABSTRACT
Objectives: The objective of this study was to determine the frequency of adverse effects (AE) of vaccination against COVID-19 in patients with SLE who visit medical centers in Asuncion, Paraguay. Method(s): The study performed was observational, transverse, descriptive. 152 patients with SLE were included, who received at least one dose of anti-COVID vaccine. A survey was carried out, which allowed the data collection through phone calls or instant messaging. Each investigator had a spreadsheet that related the generated code with the surveyed patient's name. Once the call ended and if the patient agreed to participate in the study, a code was generated. Result(s): 88.5% of the individuals were female, the average age was 33.93 +/- 11,102 years. Of these, 94.3% received their first dose, 86.3% the second dose, 39.7% the third dose, and 2.3% the fourth dose. Of the total vaccinated patients, 39.38% were administered Sputnik-V, 26.02% Pfizer, 16.43% AstraZeneca, 13.35% Moderna, 4.1% Covaxin, and 0.68% Hayat Vax. Of 292 doses administered, 103 AEs were recorded, 79.6% within the first 5 days and the rest within the next 5 days. 44.03% presented the AE after the first dose, 32.11% after the second dose and 23.85% after the third dose. Themean duration of symptoms was 7.49 +/- 9.877 days. The most important side effect was pain at the injection site, followed by fever and fatigue. The worsening of Lupus due to the administration of the anticovid vaccine was demonstrated in 9.93% of the cases. Conclusion(s): Mild effects were registered. It is concluded that vaccination against COVID-19 is safe for individuals with SLE.